Page last updated: 2024-11-07

dichlororibofuranosylbenzimidazole and Experimental Leukemia

dichlororibofuranosylbenzimidazole has been researched along with Experimental Leukemia in 2 studies

Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tweeten, KA1
Molloy, GR2
Mukherjee, R1

Other Studies

2 other studies available for dichlororibofuranosylbenzimidazole and Experimental Leukemia

ArticleYear
Induction of premature termination of transcription of the mouse beta-globin gene by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB).
    Nucleic acids research, 1981, Jul-24, Volume: 9, Issue:14

    Topics: Animals; Cell Line; Clone Cells; Cloning, Molecular; Dichlororibofuranosylbenzimidazole; DNA Restric

1981
5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription of the beta-hemoglobin gene in vivo at initiation.
    The Journal of biological chemistry, 1987, Oct-05, Volume: 262, Issue:28

    Topics: Animals; Cell Line; Cell Nucleus; Dichlororibofuranosylbenzimidazole; Genes; Hemoglobins; Kinetics;

1987
chemdatabank.com